AIDS
Conditions
Keywords
Human Immunodeficiency Virus (HIV)-1, safety, vaccine, immunogenicity, reactogenicity, HIV infection
Brief summary
This study is designed to determine whether administration of the GSK Biologicals HIV vaccine 732462 can lead to a reduction in viral load, and impact on the course of human immunodeficiency virus type 1 (HIV-1) infection. In HIV-1 infected persons who have not yet started antiretroviral therapy (ART), such a vaccine would potentially lead to a delay in the initiation of treatment.
Interventions
BIOLOGICALGSK Biologicals HIV Vaccine 732462
2 or 3 doses according to protocol schedule
DRUGPlacebo
1 or 3 doses according to protocol schedule
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
All subjects must satisfy ALL the following criteria at study entry: * Subjects who the investigator believes can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject prior to any study procedure. * A male or female between and including 18-55 years at the time of first vaccination. * Known to be HIV-1 infected and under the care of an HIV physician for a minimum of 6 months. However, subjects who initially presented with a clinical diagnosis of primary HIV infection need to have been diagnosed and under care for at least 12 months. * ART-naïve. Individuals must never have received ART after HIV diagnosis, including lamivudine used for chronic hepatitis B infection, with the exception of short-term ART for prevention of mother-to-child transmission (PMTCT) at least 12 months prior to enrollment. * Commencement of ART is not expected, based on current assessment, within the next 12 months. * Viral load level of 2,000-80,000 copies/mL at screening. * CD4 count \>= 500 cells per mm3 at screening. * If the subject is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal. Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test at screening, and * has agreed to continue adequate contraception during the entire study period.
Exclusion criteria
The following criteria should be checked at the time of screening and before vaccination. If ANY exclusion criterion applies, the subject must not be included in the study: * Infection with HIV-2. This includes patients with dual infection with HIV-1/HIV-2. * Had an Acquired Immune Deficiency Syndrome (AIDS) defining clinical illness. * Use of any investigational or non-registered product within 4 weeks preceding the first dose of study vaccine/placebo, or planned use of any investigational or non-registered product other than the study vaccine during the study period. * Drug therapy with immunomodulators or steroids within the 12 weeks preceding the first dose of study vaccine/placebo or planned administration during the study period. Acute use of steroids up to 4 weeks preceding the first dose for treatment of hypersensitivity reactions is not an exclusion criterion. Inhaled and topical steroids are allowed. * Administration of immunoglobulins and/ or any blood products within the 12 weeks preceding the first dose of study vaccine/placebo or planned administration during the study period. * Planned administration of a vaccine not foreseen by the study protocol during * the period starting 2 weeks before the first dose of study vaccine/placebo and ending at Visit 3 (Week 6) (after blood sampling), * the period starting from 2 weeks prior to Visit 5 (Week 28) and ending at Visit 6 (Week 30) (after blood sampling) * the period starting from 2 weeks prior to Visit 8 (Week 48) and ending at Visit 8 (Week 48) (after blood sampling), with the exception of non-adjuvanted influenza vaccine. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * Any previous vaccination or immunotherapy against HIV. * A family history of hereditary immunodeficiency. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Acute or chronic infective hepatitis. * Acute or chronic, clinically relevant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination and/or medical history at screening. * Grade 3 or grade 4 laboratory abnormality, as defined by Division od AIDS (DAIDS) grading table, at screening * Pregnant or lactating female. * Any condition which, in the opinion of the investigator, could compromise the subject's safety or adherence to the study protocol. * History of medically confirmed autoimmune disease. * History of malignancy, other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure. * Unstable asthma * Food or wine induced asthma. * Known sensitivity to sulfites or aspirin. * Known sensitivity to aminoglycoside antibiotics. * Contraindication to intramuscular injection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Change in Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load (VL) From Baseline | At Week 48, post-Dose 3 | Changes from baseline in HIV-1 viral load (ratio of each value over baseline value) were obtained using crude values and expressed in RNA copies/milliliter \[copies/mL\]. Baseline of HIV-1 viral load was defined as geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic. |
| Geometric Mean Change in HIV-1 VL From Baseline | At Week 48, post-Dose 3 | Changes from baseline in HIV-1 viral load (difference of each value minus baseline value) were obtained using log10-transformed values and expressed in log10-RNA copies/mL. Baseline of HIV-1 viral load was defined as geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic. |
| Number of Subjects With Solicited Local Symptoms | During the 7-day (Days 0-6) period following Dose 1 | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of symptom regardless of intensity. Grade 3 Pain = pain that prevented normal every day activities. Grade 3 Redness/Swelling = redness or swelling associated with ulceration or secondary infection/phlebitis/sterile abscess/drainage. Medically attended (MA) Pain = pain causing inability to perform basic self-care function or Hospitalization indicated for management of pain. Medically attended Redness/Swelling = redness or swelling associated with necrosis. |
| Number of Subjects With Solicited General Symptoms | During the 7-day (Days 0-6) period following Dose 1 | Assessed solicited general symptoms(smt.)were abdominalpain,anorexia,diarrhoea,fatigue,headache,myalgia,nausea,sweating,temperature(Temp.)orally=temp.37.7degreesCelsius(°C)&vomiting.Any=occurrene of smt.regardless of intensity.Grade3(G3)Abdominal pain/fatigue/myalgia/sweating/headache=symp.causing inability to perform usual social&functional activities.Medicallyattended(MA)Abdominalpain/fatigue/myalgia/sweating/headache=smt.causing inability to perform basic self-care activities.G3Anorexia=loss of appetite associated with significant weight loss.MAanorexia=aggressive intervention indicated.G3diarrhoea=blood/increased≥7stools per24hours(h)/4fluid replacement.G3nausea=persistent nausea resulting in minimal oral intake for more than48h/with aggressive rehydration indicated.G3vomiting=persistent vomiting resulting in orthostatic hypotension/aggressive.MAdiarrhoea/nausea/vomiting=smt.with life threatening consequences.Related=smt.assessed by the investigator as being related to vaccination |
| Number of Subjects With Potentially Immune-Mediated Diseases (pIMDs) | During the entire study period (up to Week 48) | Potentially Immune-Mediated Diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. |
| Number of Subjects With Unsolicited Adverse Events (AEs) | During the 28-Day (Days 0-27) period following Dose 1 and Dose 2 | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 (G3) AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were tabulated following Dose 1 and Dose 2 vaccinations. |
| Number of Subjects With Unsolicited AEs | During the 28-Day (Days 0-27) post-vaccination period | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 (G3) AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were tabulated following Dose 3 and across doses. |
| Number of Subjects With Serious Adverse Events (SAEs) | During the entire study period (up to Week 48) | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Abnormal Haematological and Biochemical Values | At Screening | Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD40L+CD4+ T-cells and F4co-Computed \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD40L+CD4+ T-cells expressing at least interleukin- 2 (IL-2) or another cytokine among interferon-gamma (IFN-γ) and/or tumour necrosis-alpha (TNF-α), as assessed by Intracellular Cytokine Staining (ICS). |
| Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD40L-CD4+ T-cells and F4co-Computed \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD40L-CD4+ T-cells expressing at least interleukin- 2 (IL-2) or another cytokine among interferon-gamma (IFN-γ) and/or tumour necrosis-alpha (TNF-α), as assessed by Intracellular Cytokine Staining (ICS). |
| Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD4+ T-cells and F4co-Computed \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD4+ T-cells expressing at least interleukin- 2 (IL-2) or another cytokine among interferon-gamma (IFN-γ) and/or tumour necrosis-alpha (TNF-α), as assessed by Intracellular Cytokine Staining (ICS). |
| Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD8+ T-cells and F4co-Computed \[frequency of CD8+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD8+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD8+ T-cells expressing at least interleukin- 2 (IL-2) or another cytokine among interferon-gamma (IFN-γ) and/or tumour necrosis-alpha (TNF-α), as assessed by Intracellular Cytokine Staining (ICS). |
| Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Breadth was assessed only for the CD4+ T-cells and was measured by evaluating response to at least 1, 2, 3 or all 4 antigens: proteins 17, 24, Nef, reverse transcriptase (RT). |
| Cytokine Expression Profile of F4co-Computed CD4+ T Cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of F4co-Computed CD4+ T-cells \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ). |
| Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of Nef-specific CD4+ T-cells expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ). |
| Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of P17-specific CD4+ T-cells expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ). |
| Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of P24-specific CD4+ T-cells expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ). |
| Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of reverse transcriptase (RT)-specific CD4+ T-cells expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ). |
| Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | At Weeks 1, 4, 6, 16, 28, 30 and 38 | Changes from baseline in HIV-1 viral load (ratio of each value over baseline value) were obtained using crude values and expressed in RNA copies/mL. Baseline of HIV-1 viral load was defined as the geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic. Changes from baseline were measured at Week 1 to 28 for the HIV Group, Weeks 30 and 38 for the 3D\_HIV Group and 2D\_HIV Group and from Week 1 to Week 38 for the Control Group. |
| Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of Nef-specific CD8+ T-cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ. |
| Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of P17-specific CD8+ T-cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ. |
| Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of P24-specific CD8+ T-cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ. |
| Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of reverse transcriptase (RT)-specific CD8+ T-cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ. |
| Number of Seropositive Subjects for Anti-P17 Antibodies | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Seropositivity rates for antibodies against P17 antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 187 milli-ELISA units per milliliter (mEL.U/mL). |
| Number of Seropositive Subjects for Anti-P24 Antibodies | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Seropositivity rates for antibodies against P24 antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 119 milli-ELISA units per milliliter (mEL.U/mL). |
| Number of Seropositive Subjects for Anti-Nef Antibodies | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Seropositivity rates for antibodies against Nef antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 494 milli-ELISA units per milliliter (mEL.U/mL). |
| Number of Seropositive Subjects for Anti-RT Antibodies | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Seropositivity rates for antibodies against RT antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 125 milli-ELISA units per milliliter (mEL.U/mL). |
| Number of Seropositive Subjects for Anti-F4co Antibodies | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Seropositivity rates for antibodies against F4co antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 42 milli-ELISA units per milliliter (mEL.U/mL). |
| Cytokine Expression Profile of F4co-Computed CD8+ T Cells | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | The cytokine co-expression profile was defined by the frequency of F4co-Computed CD8+ T-cells \[Frequency of CD8+ T cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD8+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ. |
| Geometric Mean Change in HIV-1 VL From Baseline | At Weeks 1, 4, 6, 16, 28, 30 and 38 | Changes from baseline in HIV-1 viral load (difference of each value minus baseline value) were obtained using log10-transformed values and expressed in log10-RNA copies/mL. Baseline of HIV-1 viral load was defined as geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic. Changes from baseline were measured at Week 1 to 29 for the HIV Group, Weeks 30 and 38 for the 3D\_HIV Group and 2D\_HIV Group and from Week 1 to Week 38 for the Control Group. |
| Levels of HIV-1 Viral Load (VL) | At Screening, Pre-vaccination and at Weeks 1, 4, 6, 16, 28, 30, 38 and 48 | HIV-1 VL, using crude values, was expressed in RNA copies/mL and measured from Screening to Week 28 for the HIV Group, Weeks 30, 38 and 48 for the 3D\_HIV Group and 2D\_HIV Group and from Screening to Week 48 for the Control Group. |
| Levels of HIV-1 VL | At Screening, Pre-vaccination and at Weeks 1, 4, 6, 16, 28, 30, 38 and 48 | HIV-1 VL, using log10 transformed values, was expressed in log10-RNA copies/mL and measured from Screening to Week 28 for the HIV Group, Weeks 30, 38 and 48 for the 3D\_HIV Group and 2D\_HIV Group and from Screening to Week 48 for the Control Group. |
| Percentage of Subjects With Plasmatic HIV-1 Viral Load Decrease Higher Than (>) 1 | At Week 48 | The proportion of subjects with \>1 decrease of HIV-1 VL, was determined using log10-transformed values. |
| Cluster of Differentiation 4 (CD4) Absolute Cell Count | At Screening, Pre-vaccination and at Weeks 1, 4, 6, 16, 28, 30, 38 and 48 | Result determination, using crude values, was done from Screening to Week 28 for the HIV Group, Weeks 30, 38 and 48 for the 3D\_HIV Group and 2D\_HIV Group and from Screening (SCR) to Week (W) 48 for the Control Group. |
| Mean Change in CD4 Cell Count From Baseline | At Weeks 1, 4, 6, 16, 28, 30, 38 and 48 | Baseline for CD4 cell count analysis was defined as the mean of values measured in blood taken at Screening and at pre vaccination (PRE). Result determination, using crude values, was done from week 1 to 28 for the HIV Group, weeks 30, 38 and 48 for the 3D\_HIV Group and 2D\_HIV Group and from week 1 to week 48 for the Control Group. |
| Percentage of Subjects With ART (Anti-Retroviral Therapy) Initiation and HIV-related Clinical Events | During the entire study period (up to Week 48) | Only actual ART initiations were reported under the category ART initiation. HIV-related clinical events were defined as: clinical disease progression, or confirmed VL \> 100.000 copies/mL, or confirmed CD4 cell count \< 350 cells/ cubic millimeter (mm3). |
| Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group) | Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD40L+CD4+ T-cells and F4co-Computed \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD40L+CD4+ T-cells expressing at least interleukin- 2 (IL-2), as assessed by Intracellular Cytokine Staining (ICS). |
Countries
France, Germany, Spain, United States
Participant flow
Pre-assignment details
Out of 191 subjects originally enrolled in the study, only 190 subjects received vaccination and were hence included in the Total Vaccinated Cohort.
Participants by arm
| Arm | Count |
|---|---|
| 3D_HIV Group HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of the HIV Vaccine 732462 at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm. | 62 |
| 2D_HIV Group HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 2 doses of the HIV Vaccine 732462 at Weeks 0 and 4 and one dose of placebo (saline solution) at Week 28, administered intramuscularly in the deltoid of the non-dominant arm. | 64 |
| Control Group HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of placebo (saline solution) at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm. | 64 |
| Total | 190 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 4 | 1 | 4 |
| Overall Study | Protocol Deviation Eligibility Criteria | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 0 | 1 |
Baseline characteristics
| Characteristic | 3D_HIV Group | 2D_HIV Group | Control Group | Total |
|---|---|---|---|---|
| Age, Continuous | 34.9 Years STANDARD_DEVIATION 7.6 | 37.0 Years STANDARD_DEVIATION 8.2 | 35.9 Years STANDARD_DEVIATION 8.4 | 35.9 Years STANDARD_DEVIATION 8.1 |
| Race/Ethnicity, Customized Race/Ethnicity African heritage/African American | 11 Participants | 10 Participants | 15 Participants | 36 Participants |
| Race/Ethnicity, Customized Race/Ethnicity American Indian or Alaskan Native | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Race/Ethnicity Other | 4 Participants | 0 Participants | 2 Participants | 6 Participants |
| Race/Ethnicity, Customized Race/Ethnicity White-Arabic/North African heritage | 4 Participants | 3 Participants | 3 Participants | 10 Participants |
| Race/Ethnicity, Customized Race/Ethnicity White-Caucasian/European heritage | 43 Participants | 51 Participants | 42 Participants | 136 Participants |
| Sex: Female, Male Female | 9 Participants | 10 Participants | 10 Participants | 29 Participants |
| Sex: Female, Male Male | 53 Participants | 54 Participants | 54 Participants | 161 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 62 | 0 / 64 | 0 / 64 |
| other Total, other adverse events | 60 / 62 | 60 / 64 | 42 / 64 |
| serious Total, serious adverse events | 1 / 62 | 3 / 64 | 2 / 64 |
Outcome results
Primary
Geometric Mean Change in HIV-1 VL From Baseline
Changes from baseline in HIV-1 viral load (difference of each value minus baseline value) were obtained using log10-transformed values and expressed in log10-RNA copies/mL. Baseline of HIV-1 viral load was defined as geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic.
Time frame: At Week 48, post-Dose 3
Population: The analysis was performed on the Modified Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 3D_HIV Group | Geometric Mean Change in HIV-1 VL From Baseline | 0.0 log10(RNA copies/mL) | Standard Deviation 0.35 |
| 2D_HIV Group | Geometric Mean Change in HIV-1 VL From Baseline | 0.2 log10(RNA copies/mL) | Standard Deviation 0.38 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | 0.1 log10(RNA copies/mL) | Standard Deviation 0.34 |
Comparison: To show the difference in change from baseline of HIV-1 VL (log10-transformed values) at week 48 between persons who received 3 doses of the HIV Vaccine 732462 and persons who received placebo alone.97.5% CI: [-0.257, 0.065]Repeated-measures mixed model
Comparison: To show the difference in change from baseline of HIV-1 VL (log10-transformed values) at week 48 between persons who received 2 doses of the HIV Vaccine 732462 and persons who received placebo alone.97.5% CI: [-0.088, 0.235]Repeated-measures mixed model
Primary
Geometric Mean Change in Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load (VL) From Baseline
Changes from baseline in HIV-1 viral load (ratio of each value over baseline value) were obtained using crude values and expressed in RNA copies/milliliter \[copies/mL\]. Baseline of HIV-1 viral load was defined as geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic.
Time frame: At Week 48, post-Dose 3
Population: The analysis was performed on the Modified Total vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 3D_HIV Group | Geometric Mean Change in Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load (VL) From Baseline | 1.0 RNA copies/mL | Standard Deviation 0.35 |
| 2D_HIV Group | Geometric Mean Change in Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load (VL) From Baseline | 1.5 RNA copies/mL | Standard Deviation 0.38 |
| Control Group | Geometric Mean Change in Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load (VL) From Baseline | 1.3 RNA copies/mL | Standard Deviation 0.34 |
Comparison: To show the difference in change from baseline of HIV-1 VL at week 48 between persons who received 3 doses of the HIV vaccine 732462 and persons who received placebo alone.97.5% CI: [0.553, 1.162]Repeated-measures mixed model
Comparison: To show the difference in change from baseline of HIV-1 VL at week 48 between persons who received 2 doses of the HIV Vaccine 732462 and persons who received placebo alone.97.5% CI: [0.816, 1.717]Repeated-measures mixed model
Primary
Number of Subjects With Abnormal Haematological and Biochemical Values
Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).
Time frame: At Week 38
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 56 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 54 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 56 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 56 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 51 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 53 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 46 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 11 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 57 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 55 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 57 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 57 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 54 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 55 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 54 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 52 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 54 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 55 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 47 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 52 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 5 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 10 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 52 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 3 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 55 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 61 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 61 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 2 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 61 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 61 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 2 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 51 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 12 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 61 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 2 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 61 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 2 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 59 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 3 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 7 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 59 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Values
Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).
Time frame: At Week 30
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 57 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 55 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 51 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 57 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 55 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 53 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 43 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 15 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 57 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 53 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 55 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 55 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 45 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 12 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 55 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 53 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 51 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 6 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 54 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 54 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 58 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 56 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 4 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 15 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 45 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 59 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 57 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 59 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 59 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 58 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 2 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 59 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Values
Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).
Time frame: At Week 28
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 1 and Dose 2 vaccinations were identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 112 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 115 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 119 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 119 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 92 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 29 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 120 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 120 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 115 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 115 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 118 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 110 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 11 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 54 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 59 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 59 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 6 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 59 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 45 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 15 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 59 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 58 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Values
Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).
Time frame: At Week 16
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 1 and Dose 2 vaccinations were identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 113 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 10 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 123 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 122 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 117 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 119 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 93 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 31 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 122 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 123 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 119 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 111 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 13 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 59 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 55 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 59 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 6 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 58 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 47 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 14 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Values
Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).
Time frame: At Week 6
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 1 and Dose 2 vaccinations were identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 117 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 123 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 118 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 119 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 92 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 33 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 117 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 122 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 118 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 51 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 11 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 58 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 39 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 23 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Values
Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).
Time frame: At Week 4
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 1 and Dose 2 vaccinations were identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 114 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 10 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 119 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 122 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 123 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 119 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 115 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 11 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 99 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 27 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 126 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 48 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 15 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 60 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 54 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 9 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Values
Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).
Time frame: Pre-vaccination, at Week 0
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 1 vaccination was identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 100 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 117 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 26 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 114 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 11 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 123 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 121 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 118 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 125 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 59 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 5 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 61 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 47 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 17 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 55 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 9 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Values
Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).
Time frame: At Screening
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since the screening timepoint was identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 125 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 115 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 120 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 11 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 119 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 115 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 124 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 122 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 118 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 8 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 123 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 116 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 10 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 9 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 126 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 62 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 59 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 5 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 63 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 59 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 64 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 1 Participants |
Primary
Number of Subjects With Abnormal Haematological and Biochemical Values
Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).
Time frame: At Week 48
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 57 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 55 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 56 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 54 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 48 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 57 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 8 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 9 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 49 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 52 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 58 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 55 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 55 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 53 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 55 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 55 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 54 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 43 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 14 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 56 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 57 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 0 | 58 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 0 | 51 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 1 | 12 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 1 | 5 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTT, Grade 0 | 58 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 1 | 5 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 2 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | HGB, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 0 | 61 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PLC, Grade 0 | 62 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | AST, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 1 | 2 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALP, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU/100LEU, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | BIL, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 0 | 60 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 0 | 62 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 1 | 1 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM/100LEU, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALB, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | CRE, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | PTS, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 0 | 63 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | NEU, Grade 1 | 3 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 1 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 2 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 1 | 2 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | SDI, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 3 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | ALT, Grade 0 | 61 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | LYM, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | WBC, Grade 4 | 0 Participants |
| Control Group | Number of Subjects With Abnormal Haematological and Biochemical Values | EOS/100LEU, Grade 4 | 0 Participants |
Primary
Number of Subjects With Potentially Immune-Mediated Diseases (pIMDs)
Potentially Immune-Mediated Diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Time frame: During the entire study period (up to Week 48)
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 3D_HIV Group | Number of Subjects With Potentially Immune-Mediated Diseases (pIMDs) | 0 Participants |
| 2D_HIV Group | Number of Subjects With Potentially Immune-Mediated Diseases (pIMDs) | 1 Participants |
| Control Group | Number of Subjects With Potentially Immune-Mediated Diseases (pIMDs) | 0 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (up to Week 48)
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 3D_HIV Group | Number of Subjects With Serious Adverse Events (SAEs) | 1 Participants |
| 2D_HIV Group | Number of Subjects With Serious Adverse Events (SAEs) | 3 Participants |
| Control Group | Number of Subjects With Serious Adverse Events (SAEs) | 2 Participants |
Primary
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms(smt.)were abdominalpain,anorexia,diarrhoea,fatigue,headache,myalgia,nausea,sweating,temperature(Temp.)orally=temp.37.7degreesCelsius(°C)&vomiting.Any=occurrene of smt.regardless of intensity.Grade3(G3)Abdominal pain/fatigue/myalgia/sweating/headache=symp.causing inability to perform usual social&functional activities.Medicallyattended(MA)Abdominalpain/fatigue/myalgia/sweating/headache=smt.causing inability to perform basic self-care activities.G3Anorexia=loss of appetite associated with significant weight loss.MAanorexia=aggressive intervention indicated.G3diarrhoea=blood/increased≥7stools per24hours(h)/4fluid replacement.G3nausea=persistent nausea resulting in minimal oral intake for more than48h/with aggressive rehydration indicated.G3vomiting=persistent vomiting resulting in orthostatic hypotension/aggressive.MAdiarrhoea/nausea/vomiting=smt.with life threatening consequences.Related=smt.assessed by the investigator as being related to vaccination
Time frame: During the 7-day (Days 0-6) period following Dose 3
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented, who had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Dose 3 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Headache, Dose 3 | 8 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Dose 3 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Dose 3 | 25 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Dose 3 | 8 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Dose 3 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Dose 3 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Dose 3 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal pain, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Abdominal pain, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Dose 3 | 19 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Dose 3 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal pain, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Dose 3 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Headache, Dose 3 | 16 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Dose 3 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Dose 3 | 13 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Dose 3 | 15 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Dose 3 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Dose 3 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attende Abdominal pain, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Dose 3 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Dose 3 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Dose 3 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Dose 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Dose 3 | 11 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Dose 3 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Dose 3 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Headache, Dose 3 | 17 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Dose 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Headache, Dose 3 | 5 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Dose 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Dose 3 | 9 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Dose 3 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Dose 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Dose 3 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal pain, Dose 3 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Dose 3 | 8 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Abdominal pain, Dose 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal pain, Dose 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attende Abdominal pain, Dose 3 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Dose 3 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Dose 3 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Dose 3 | 12 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Dose 3 | 3 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Dose 3 | 5 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Dose 3 | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Dose 3 | 3 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Dose 3 | 2 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Dose 3 | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Dose 3 | 2 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal pain, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Abdominal pain, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal pain, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attende Abdominal pain, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Dose 3 | 3 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Dose 3 | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Dose 3 | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Dose 3 | 8 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Dose 3 | 2 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Headache, Dose 3 | 7 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Headache, Dose 3 | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Dose 3 | 4 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Dose 3 | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Dose 3 | 0 Participants |
Primary
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms(smt.)were abdominalpain,anorexia,diarrhoea,fatigue,headache,myalgia,nausea,sweating,temperature(Temp.)orally=temp.37.7degreesCelsius(°C)&vomiting.Any=occurrene of smt.regardless of intensity.Grade3(G3)Abdominal pain/fatigue/myalgia/sweating/headache=symp.causing inability to perform usual social&functional activities.Medicallyattended(MA)Abdominalpain/fatigue/myalgia/sweating/headache=smt.causing inability to perform basic self-care activities.G3Anorexia=loss of appetite associated with significant weight loss.MAanorexia=aggressive intervention indicated.G3diarrhoea=blood/increased≥7stools per24hours(h)/4fluid replacement.G3nausea=persistent nausea resulting in minimal oral intake for more than48h/with aggressive rehydration indicated.G3vomiting=persistent vomiting resulting in orthostatic hypotension/aggressive.MAdiarrhoea/nausea/vomiting=smt.with life threatening consequences.Related=smt.assessed by the investigator as being related to vaccination
Time frame: During the 7-day (Days 0-6) period following Dose 1
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented, who had their symptom sheets filled in. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 1 vaccination was identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal pain, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Abdominal pain, Dose 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal pain, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Abdominal pain, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Dose 1 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Dose 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Dose 1 | 16 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Dose 1 | 14 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Dose 1 | 56 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Dose 1 | 24 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Headache, Dose 1 | 40 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Dose 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Headache, Dose 1 | 16 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Dose 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Dose 1 | 44 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Dose 1 | 26 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Dose 1 | 17 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Dose 1 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Dose 1 | 16 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Dose 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Dose 1 | 8 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Dose 1 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Dose 1 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Dose 1 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Dose 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Dose 1 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Dose 1 | 9 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal pain, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Abdominal pain, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal pain, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Abdominal pain, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Dose 1 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Dose 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Dose 1 | 5 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Dose 1 | 5 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Dose 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Dose 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Dose 1 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Dose 1 | 16 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Dose 1 | 7 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Headache, Dose 1 | 14 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Dose 1 | 6 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Dose 1 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Headache, Dose 1 | 8 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Dose 1 | 1 Participants |
Primary
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms(smt.)were abdominalpain,anorexia,diarrhoea,fatigue,headache,myalgia,nausea,sweating,temperature(Temp.)orally=temp.37.7degreesCelsius(°C)&vomiting.Any=occurrene of smt.regardless of intensity.Grade3(G3)Abdominal pain/fatigue/myalgia/sweating/headache=symp.causing inability to perform usual social&functional activities.Medicallyattended(MA)Abdominalpain/fatigue/myalgia/sweating/headache=smt.causing inability to perform basic self-care activities.G3Anorexia=loss of appetite associated with significant weight loss.MAanorexia=aggressive intervention indicated.G3diarrhoea=blood/increased≥7stools per24hours(h)/4fluid replacement.G3nausea=persistent nausea resulting in minimal oral intake for more than48h/with aggressive rehydration indicated.G3vomiting=persistent vomiting resulting in orthostatic hypotension/aggressive.MAdiarrhoea/nausea/vomiting=smt.with life threatening consequences.Related=smt.assessed by the investigator as being related to vaccination
Time frame: During the 7-day (Days 0-6) period following Dose 2
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented, who had their symptom sheets filled in. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 2 vaccination was identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Dose 2 | 42 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Dose 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Dose 2 | 26 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal Pain, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Dose 2 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Dose 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Dose 2 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Dose 2 | 11 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Dose 2 | 56 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Dose 2 | 9 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Dose 2 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Dose 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Dose 2 | 25 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Dose 2 | 17 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Abdominal Pain, Dose 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Dose 2 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Dose 2 | 8 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Dose 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Dose 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Dose 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Dose 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Abdominal Pain, Dose 2 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Dose 2 | 11 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Headache, Dose 2 | 34 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Dose 2 | 13 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Dose 2 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Dose 2 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Dose 2 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Dose 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Headache, Dose 2 | 15 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Dose 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Dose 2 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal Pain, Dose 2 | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Dose 2 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal Pain, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Abdominal Pain, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal Pain, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Abdominal Pain, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Dose 2 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Dose 2 | 7 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Dose 2 | 10 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Dose 2 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Headache, Dose 2 | 8 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Headache, Dose 2 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Dose 2 | 6 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Dose 2 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Dose 2 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Dose 2 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Dose 2 | 0 Participants |
Primary
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms(smt.)were abdominalpain,anorexia,diarrhoea,fatigue,headache,myalgia,nausea,sweating,temperature(Temp.)orally=temp.37.7degreesCelsius(°C)&vomiting.Any=occurrene of smt.regardless of intensity.Grade3(G3)Abdominal pain/fatigue/myalgia/sweating/headache=symp.causing inability to perform usual social&functional activities.Medicallyattended(MA)Abdominalpain/fatigue/myalgia/sweating/headache=smt.causing inability to perform basic self-care activities.G3Anorexia=loss of appetite associated with significant weight loss.MAanorexia=aggressive intervention indicated.G3diarrhoea=blood/increased≥7stools per24hours(h)/4fluid replacement.G3nausea=persistent nausea resulting in minimal oral intake for more than48h/with aggressive rehydration indicated.G3vomiting=persistent vomiting resulting in orthostatic hypotension/aggressive.MAdiarrhoea/nausea/vomiting=smt.with life threatening consequences.Related=smt.assessed by the investigator as being related to vaccination
Time frame: During the 7-day (Days 0-6) post-vaccination period, across doses
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented, who had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Across doses | 13 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Across doses | 8 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Across doses | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Across doses | 7 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Abdominal pain, Across doses | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Across doses | 17 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Across doses | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Across doses | 24 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Across doses | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Headache, Across doses | 32 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Across doses | 11 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Across doses | 22 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Across doses | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Across doses | 4 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Headache, Across doses | 15 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Across doses | 33 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Across doses | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Across doses | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Across doses | 9 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Across doses | 5 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal pain, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Across doses | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Across doses | 14 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Across doses | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Across doses | 17 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Abdominal pain, Across doses | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Across doses | 6 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Across doses | 5 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Across doses | 11 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Across doses | 2 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal pain, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Across doses | 1 Participants |
| 3D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Across doses | 43 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Across doses | 19 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Across doses | 10 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Across doses | 14 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Across doses | 10 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal pain, Across doses | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Abdominal pain, Across doses | 3 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal pain, Across doses | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Abdominal pain, Across doses | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Across doses | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Across doses | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Across doses | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Across doses | 38 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Across doses | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Across doses | 24 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Across doses | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Across doses | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Headache, Across doses | 33 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Across doses | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Headache, Across doses | 17 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Across doses | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Across doses | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Across doses | 32 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Across doses | 5 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Across doses | 21 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Across doses | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Across doses | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Across doses | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Across doses | 20 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Across doses | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Across doses | 7 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Across doses | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Across doses | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Across doses | 9 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Across doses | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Across doses | 1 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Across doses | 2 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Abdominal pain, Across doses | 4 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Nausea, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Diarrhoea, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Temperature, Across doses | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Nausea, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Diarrhoea, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Abdominal pain, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Sweating, Across doses | 10 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Diarrhoea, Across doses | 2 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Vomiting, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Diarrhoea, Across doses | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Vomiting, Across doses | 3 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Sweating, Across doses | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Diarrhoea, Across doses | 14 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Abdominal pain, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Sweating, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Anorexia, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Vomiting, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Sweating, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Anorexia, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Vomiting, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Temperature, Across doses | 6 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Anorexia, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Abdominal pain, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Headache, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Headache, Across doses | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Headache, Across doses | 11 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Anorexia, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Myalgia, Across doses | 12 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache, Across doses | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Nausea, Across doses | 8 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Myalgia, Across doses | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Headache, Across doses | 21 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Temperature, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Myalgia, Across doses | 4 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Fatigue, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Anorexia, Across doses | 7 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Myalgia, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Fatigue, Across doses | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Vomiting, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Myalgia, Across doses | 1 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Fatigue, Across doses | 9 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Related Temperature, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Nausea, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue, Across doses | 3 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Medically Attended Abdominal pain, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Related Nausea, Across doses | 2 Participants |
| Control Group | Number of Subjects With Solicited General Symptoms | Any Fatigue, Across doses | 20 Participants |
Primary
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of symptom regardless of intensity. Grade 3 Pain = pain that prevented normal every day activities. Grade 3 Redness/Swelling = redness or swelling associated with ulceration or secondary infection/phlebitis/sterile abscess/drainage. Medically attended (MA) Pain = pain causing inability to perform basic self-care function or Hospitalization indicated for management of pain. Medically attended Redness/Swelling = redness or swelling associated with necrosis.
Time frame: During the 7-day (Days 0-6) period following Dose 1
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented, who had their symptom sheets filled in. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 1 vaccination was identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Pain, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Redness, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Dose 1 | 16 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Dose 1 | 7 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Dose 1 | 112 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Swelling, Dose 1 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 9 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Swelling, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Dose 1 | 12 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Pain, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Redness, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
Primary
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of symptom regardless of intensity. Grade 3 Pain = pain that prevented normal every day activities. Grade 3 Redness/Swelling = redness or swelling associated with ulceration or secondary infection/phlebitis/sterile abscess/drainage. Medically attended (MA) Pain = pain causing inability to perform basic self-care function or Hospitalization indicated for management of pain. Medically attended Redness/Swelling = redness or swelling associated with necrosis.
Time frame: During the 7-day (Days 0-6) post-vaccination period, across doses
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented, who had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Across doses | 17 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Swelling, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Redness, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Across doses | 58 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Pain, Across doses | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Across doses | 15 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Across doses | 4 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Across doses | 57 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Across doses | 6 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Pain, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Across doses | 14 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Redness, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Across doses | 8 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Swelling, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Pain, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Across doses | 14 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Swelling, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Redness, Across doses | 0 Participants |
Primary
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of symptom regardless of intensity. Grade 3 Pain = pain that prevented normal every day activities. Grade 3 Redness/Swelling = redness or swelling associated with ulceration or secondary infection/phlebitis/sterile abscess/drainage. Medically attended (MA) Pain = pain causing inability to perform basic self-care function or Hospitalization indicated for management of pain. Medically attended Redness/Swelling = redness or swelling associated with necrosis.
Time frame: During the 7-day (Days 0-6) period following Dose 3
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented, who had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Dose 3 | 3 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Pain, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Swelling, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Dose 3 | 42 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Dose 3 | 10 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Redness, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Redness, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Dose 3 | 9 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Swelling, Dose 3 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically attended Pain, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Medically attended Swelling, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Dose 3 | 3 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Medically attended Pain, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| Control Group | Number of Subjects With Solicited Local Symptoms | Medically attended Redness, Dose 3 | 0 Participants |
Primary
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of symptom regardless of intensity. Grade 3 Pain = pain that prevented normal every day activities. Grade 3 Redness/Swelling = redness or swelling associated with ulceration or secondary infection/phlebitis/sterile abscess/drainage. Medically attended (MA) Pain = pain causing inability to perform basic self-care function or Hospitalization indicated for management of pain. Medically attended Redness/Swelling = redness or swelling associated with necrosis.
Time frame: During the 7-day (Days 0-6) period following Dose 2
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented, who had their symptom sheets filled in. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 2 vaccination was identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 11 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Redness, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Dose 2 | 15 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Dose 2 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Pain, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Swelling, Dose 2 | 0 Participants |
| 3D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Dose 2 | 98 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Swelling, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Pain, Dose 2 | 5 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Pain, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Medically Attended Redness, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| 2D_HIV Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
Primary
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 (G3) AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were tabulated following Dose 1 and Dose 2 vaccinations.
Time frame: During the 28-Day (Days 0-27) period following Dose 1 and Dose 2
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented. For the purpose of the analysis, 3D\_HIV Group and 2D\_HIV Group were combined into a single group (HIV Group), since Dose 1 and 2 vaccinations were identical for both groups.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 9 Participants |
| 3D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Grade 3 Related AE(s) | 1 Participants |
| 3D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Related AE(s) | 6 Participants |
| 3D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Medically Attended AE(s) | 17 Participants |
| 3D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) | 58 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Medically Attended AE(s) | 13 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Any AE(s) | 29 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Grade 3 AE(s) | 3 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Related AE(s) | 2 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited Adverse Events (AEs) | Grade 3 Related AE(s) | 0 Participants |
Primary
Number of Subjects With Unsolicited AEs
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 (G3) AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were tabulated following Dose 3 and across doses.
Time frame: During the 28-Day (Days 0-27) post-vaccination period
Population: The analysis was performed on the Total Vaccinated cohort, which included subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Unsolicited AEs | Grade 3 Related AE(s) | 0 Participants |
| 3D_HIV Group | Number of Subjects With Unsolicited AEs | Related AE(s) | 2 Participants |
| 3D_HIV Group | Number of Subjects With Unsolicited AEs | Any AE(s) | 30 Participants |
| 3D_HIV Group | Number of Subjects With Unsolicited AEs | Grade 3 AE(s) | 3 Participants |
| 3D_HIV Group | Number of Subjects With Unsolicited AEs | Medically Attended AE(s) | 11 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited AEs | Related AE(s) | 6 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited AEs | Any AE(s) | 42 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited AEs | Grade 3 AE(s) | 7 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited AEs | Grade 3 Related AE(s) | 1 Participants |
| 2D_HIV Group | Number of Subjects With Unsolicited AEs | Medically Attended AE(s) | 14 Participants |
| Control Group | Number of Subjects With Unsolicited AEs | Medically Attended AE(s) | 15 Participants |
| Control Group | Number of Subjects With Unsolicited AEs | Grade 3 Related AE(s) | 0 Participants |
| Control Group | Number of Subjects With Unsolicited AEs | Any AE(s) | 34 Participants |
| Control Group | Number of Subjects With Unsolicited AEs | Related AE(s) | 2 Participants |
| Control Group | Number of Subjects With Unsolicited AEs | Grade 3 AE(s) | 3 Participants |
Secondary
Cluster of Differentiation 4 (CD4) Absolute Cell Count
Result determination, using crude values, was done from Screening to Week 28 for the HIV Group, Weeks 30, 38 and 48 for the 3D\_HIV Group and 2D\_HIV Group and from Screening (SCR) to Week (W) 48 for the Control Group.
Time frame: At Screening, Pre-vaccination and at Weeks 1, 4, 6, 16, 28, 30, 38 and 48
Population: The analysis was performed on the Modified Total vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 3D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Screening | 677.072 CD4 cells/cubic millimeter | Standard Deviation 164.31 |
| 3D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Pre-vaccination | 687.566 CD4 cells/cubic millimeter | Standard Deviation 184.41 |
| 3D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 1 | 723.91 CD4 cells/cubic millimeter | Standard Deviation 228.73 |
| 3D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 4 | 676.992 CD4 cells/cubic millimeter | Standard Deviation 182.96 |
| 3D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 6 | 691.174 CD4 cells/cubic millimeter | Standard Deviation 195.35 |
| 3D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 16 | 674.215 CD4 cells/cubic millimeter | Standard Deviation 213.69 |
| 3D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 28 | 630.836 CD4 cells/cubic millimeter | Standard Deviation 172.16 |
| 2D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 38 | 660.306 CD4 cells/cubic millimeter | Standard Deviation 202.04 |
| 2D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 48 | 636.957 CD4 cells/cubic millimeter | Standard Deviation 175.72 |
| 2D_HIV Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 30 | 649.377 CD4 cells/cubic millimeter | Standard Deviation 193.66 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 38 | 635.561 CD4 cells/cubic millimeter | Standard Deviation 174.15 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 30 | 654.448 CD4 cells/cubic millimeter | Standard Deviation 202.71 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 48 | 650.418 CD4 cells/cubic millimeter | Standard Deviation 206.12 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 30 | 662.481 CD4 cells/cubic millimeter | Standard Deviation 181.76 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 16 | 674.75 CD4 cells/cubic millimeter | Standard Deviation 186.63 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 38 | 653.154 CD4 cells/cubic millimeter | Standard Deviation 176.71 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 48 | 601.9 CD4 cells/cubic millimeter | Standard Deviation 186.81 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Screening | 688.2 CD4 cells/cubic millimeter | Standard Deviation 141.74 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Pre-vaccination | 712.407 CD4 cells/cubic millimeter | Standard Deviation 251.98 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 28 | 667.981 CD4 cells/cubic millimeter | Standard Deviation 183.53 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 1 | 711.905 CD4 cells/cubic millimeter | Standard Deviation 226.84 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 4 | 688.717 CD4 cells/cubic millimeter | Standard Deviation 186.24 |
| Control Group | Cluster of Differentiation 4 (CD4) Absolute Cell Count | CD4, Week 6 | 687.883 CD4 cells/cubic millimeter | Standard Deviation 202.79 |
Secondary
Cytokine Expression Profile of F4co-Computed CD4+ T Cells
The cytokine co-expression profile was defined by the frequency of F4co-Computed CD4+ T-cells \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 28 | 4.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 48 | 187.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 48 | 329.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 30 | 103.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 30 | 953.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Pre-vaccination | 149.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 48 | 18.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 6 | 411.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 30 | 291.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 6 | 499.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 48 | 74.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 6 | 355.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 28 | 312.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 28 | 199.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 28 | 111.5 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Pre-vaccination | 250.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 28 | 123.5 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 30 | 377.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 48 | 367.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 48 | 4.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 48 | 172.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 6 | 127.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Pre-vaccination | 201.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 30 | 36.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 6 | 346.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 6 | 341.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 6 | 416.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Pre-vaccination | 118.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 28 | 560.5 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 747.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 28 | 152.5 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 30 | 110.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 28 | 242.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 149.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 30 | 413.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 6 | 19.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 6 | 889.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 48 | 164.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 48 | 92.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Pre-vaccination | 229.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 28 | 13.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 30 | 389.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 48 | 72.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 6 | 375.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Pre-vaccination | 94.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 235.5 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 30 | 336.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 48 | 341.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 30 | 452.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 30 | 28.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 30 | 325.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 6 | 40.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 28 | 88.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 48 | 202.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Pre-vaccination | 352.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Pre-vaccination | 23.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Pre-vaccination | 110.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 28 | 180.5 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 367.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 6 | 54.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 106.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 48 | 383.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 6 | 331.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Pre-vaccination | 772.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 28 | 289.5 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 30 | 76.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 28 | 63.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 46.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 48 | 36.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 6 | 132.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 28 | 45.5 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 30 | 439.0 F4co-computed CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 624.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 30 | 142.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 6 | 27.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 30 | 244.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 28 | 4.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Pre-vaccination | 45.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 30 | 4.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 48 | 4.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 28 | 247.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Pre-vaccination | 92.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 6 | 123.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 93.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 28 | 141.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 6 | 529.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 30 | 127.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 48 | 98.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Pre-vaccination | 109.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 6 | 72.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 28 | 59.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 48 | 4.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 30 | 92.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 48 | 58.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 30 | 4.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Pre-vaccination | 251.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 110.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 6 | 251.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 28 | 10.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 28 | 135.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 30 | 760.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 30 | 101.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 6 | 21.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 48 | 192.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Pre-vaccination | 396.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 6 | 472.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 6 | 448.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 28 | 454.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Pre-vaccination | 299.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 48 | 129.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 30 | 432.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 48 | 418.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 30 | 149.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Pre-vaccination | 149.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 6 | 320.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 28 | 131.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 28 | 196.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 132.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 6 | 264.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 48 | 218.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Pre-vaccination | 116.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 147.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 6 | 275.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 152.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 28 | 101.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 28 | 453.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 30 | 144.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 48 | 58.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Pre-vaccination | 208.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 48 | 160.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 30 | 77.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 6 | 233.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 28 | 186.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 28 | 87.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 30 | 195.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 48 | 202.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 441.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 6 | 208.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 6 | 65.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 28 | 20.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 48 | 481.5 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 45.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 30 | 17.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 48 | 4.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 48 | 174.0 F4co-computed CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 6 | 730.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Pre-vaccination | 453.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 6 | 427.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 28 | 506.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Pre-vaccination | 70.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 6 | 91.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 28 | 63.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Pre-vaccination | 250.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 6 | 277.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 28 | 163.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Pre-vaccination | 383.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 6 | 426.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 28 | 377.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Pre-vaccination | 149.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 6 | 430.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 28 | 198.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Pre-vaccination | 154.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 6 | 374.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 28 | 129.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Pre-vaccination | 224.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 6 | 280.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 28 | 181.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Pre-vaccination | 20.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 6 | 60.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 28 | 27.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 6 | 21.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 28 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Pre-vaccination | 93.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 6 | 127.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 28 | 129.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Pre-vaccination | 110.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 28 | 286.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 46.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 6 | 253.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 28 | 87.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 150.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 6 | 289.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 28 | 131.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 6 | 32.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 28 | 12.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 95.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 532.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 205.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 48 | 6.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 48 | 81.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 30 | 10.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 28 | 24.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 146.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 43.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Week 6 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 28 | 442.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 6 | 68.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 30 | 254.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 28 | 239.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 6 | 153.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 28 | 37.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 6 | 307.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Pre-vaccination | 209.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 30 | 55.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 48 | 201.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 30 | 195.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ_IL-2, Week 48 | 53.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 28 | 130.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Week 6 | 110.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 72.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 154.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α, Pre-vaccination | 88.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 30 | 96.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 91.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 6 | 172.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 28 | 56.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 6 | 127.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Pre-vaccination | 149.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 28 | 154.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Pre-vaccination | 77.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 48 | 487.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 30 | 142.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 30 | 479.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 28 | 536.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ, Week 48 | 121.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Week 6 | 563.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ, Pre-vaccination | 446.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Pre-vaccination | 493.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 48 | 182.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 30 | 223.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 28 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 6 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 28 | 216.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Week 6 | 166.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 108.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 28 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α, Pre-vaccination | 178.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 48 | 86.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 30 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 30 | 46.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 28 | 34.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ_IL-2, Week 48 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Week 6 | 58.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IL-2, Pre-vaccination | 93.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IFN- γ, Week 48 | 227.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 131.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 48 | 653.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 48 | 143.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L, Week 30 | 716.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Pre-vaccination | 126.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 30 | 153.5 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 28 | 90.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 6 | 134.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | TNF-α_IFN- γ, Week 6 | 165.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 48 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_IL-2, Week 48 | 102.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 28 | 114.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 30 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | IFN- γ_IL-2, Week 6 | 4.0 F4co-computed CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD4+ T Cells | CD40L_TNF-α_IL-2, Week 30 | 182.5 F4co-computed CD4+ T-cells/million cells |
Secondary
Cytokine Expression Profile of F4co-Computed CD8+ T Cells
The cytokine co-expression profile was defined by the frequency of F4co-Computed CD8+ T-cells \[Frequency of CD8+ T cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD8+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ.
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Pre-vaccination | 183.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 6 | 93.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 48 | 68.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 28 | 1563.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 6 | 227.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 28 | 167.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Pre-vaccination | 79.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 28 | 195.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 28 | 76.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 30 | 985.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 30 | 176.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Pre-vaccination | 1049.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 28 | 15.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 48 | 246.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 30 | 51.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Pre-vaccination | 19.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 48 | 993.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 30 | 197.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 6 | 27.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Pre-vaccination | 13049.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 28 | 23.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 28 | 192.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 6 | 9.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 6 | 15467.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 30 | 17.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 48 | 31.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 28 | 16351.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 48 | 83.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 30 | 80.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 6 | 76.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Pre-vaccination | 17.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 30 | 13512.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 6 | 957.5 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 48 | 33.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 48 | 14423.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Pre-vaccination | 72.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 48 | 84.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Pre-vaccination | 71.0 F4co-Computed CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 6 | 70.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 6 | 111.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Pre-vaccination | 98.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 28 | 66.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 30 | 103.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 48 | 80.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Pre-vaccination | 1820.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 6 | 1864.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 28 | 1782.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 6 | 149.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 30 | 1904.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 48 | 1900.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 28 | 114.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 48 | 19.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 30 | 152.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 48 | 83.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Pre-vaccination | 213.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 30 | 22.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 6 | 267.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 28 | 158.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Pre-vaccination | 204.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 28 | 19.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 30 | 179.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 48 | 200.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 6 | 18.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Pre-vaccination | 16362.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 6 | 17126.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Pre-vaccination | 36.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 28 | 14143.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 30 | 14730.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 48 | 18658.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 6 | 110.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 28 | 200.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Pre-vaccination | 21.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 6 | 24.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 30 | 143.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 28 | 19.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 48 | 21.5 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 48 | 64.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Pre-vaccination | 102.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 28 | 124.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 6 | 119.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Pre-vaccination | 100.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 28 | 174.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Pre-vaccination | 83.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 6 | 96.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Pre-vaccination | 192.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 6 | 244.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 28 | 178.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Pre-vaccination | 15324.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 6 | 16697.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 28 | 14770.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Pre-vaccination | 21.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 6 | 25.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 28 | 21.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Pre-vaccination | 84.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 6 | 84.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 28 | 71.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Pre-vaccination | 1469.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 6 | 1610.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 28 | 1563.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Pre-vaccination | 30.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 6 | 16.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 28 | 17.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Pre-vaccination | 117.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 30 | 95.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 48 | 28.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 48 | 179.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 30 | 45.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 28 | 22.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Week 6 | 25.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 28 | 108.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 48 | 20890.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 30 | 4.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 30 | 25319.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ, Week 48 | 17.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 28 | 21406.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Week 6 | 25219.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 6 | 179.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Pre-vaccination | 40.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ, Pre-vaccination | 21932.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 48 | 273.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Pre-vaccination | 223.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 6 | 58.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 30 | 240.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 28 | 227.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 28 | 21.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Week 6 | 242.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α, Pre-vaccination | 314.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 30 | 30.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 30 | 74.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 28 | 80.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN_IL-2, Week 48 | 26.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Week 6 | 50.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IL-2, Pre-vaccination | 81.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 30 | 2260.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 48 | 1787.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 28 | 2012.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Week 6 | 2199.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_IFN- γ, Pre-vaccination | 35.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | TNF-α_IFN- γ, Pre-vaccination | 2095.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 48 | 81.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 6 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 30 | 74.5 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 28 | 100.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L, Week 48 | 66.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | CD40L_TNF-α_IL-2, Week 28 | 4.0 F4co-Computed CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of F4co-Computed CD8+ T Cells | IFN- γ_IL-2, Week 6 | 119.0 F4co-Computed CD8+ T-cells/million cells |
Secondary
Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells
The cytokine co-expression profile was defined by the frequency of Nef-specific CD4+ T-cells expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 14.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 6 | 22.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 28 | 4.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 30 | 19.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 18.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 31.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 5.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 43.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 82.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 84.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 101.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 24.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 83.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 61.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 111.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 25.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 112.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 6.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 75.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 2.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 141.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 22.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 31.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 59.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 10.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 15.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 7.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 26.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 18.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 14.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 207.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 74.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 327.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 78.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 44.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 74.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 17.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 43.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 77.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 26.0 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 142.5 Nef-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 43.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 16.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 7.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 38.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 7.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 57.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 21.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 110.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 8.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 13.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 65.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 3.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 42.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 45.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 2.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 7.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 3.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 37.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 53.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 11.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 7.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 69.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 14.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 9.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 31.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 118.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 12.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 114.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 105.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 6.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 6 | 7.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 62.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 30 | 98.5 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 15.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 32.0 Nef-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 78.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 21.5 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 6.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 17.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 46.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 3.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 31.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 66.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 15.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 20.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 15.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 137.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 67.5 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 19.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 6 | 14.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.5 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 22.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 32.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 83.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 103.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 67.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 87.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 99.5 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 81.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 7.5 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 20.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 101.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 16.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 79.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 24.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 17.5 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 14.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 16.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 20.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.5 Nef-specific CD4+ T-cells/million cells |
Secondary
Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells
The cytokine co-expression profile was defined by the frequency of Nef-specific CD8+ T-cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ.
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 161.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 152.5 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 157.5 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 8.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 30 | 5.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 32.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 12.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 28 | 16.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 18.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 2947.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 2942.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 2396.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 2586.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 2236.5 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 110.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 138.0 Nef-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 191.5 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 11.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 256.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 216.5 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 2150.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 174.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 2951.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 11.5 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 19.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 19.5 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 2850.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 18.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 2778.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 2228.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 4.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 6 | 6.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 28 | 12.5 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 28 | 14.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 30 | 35.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 21.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 31.5 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 9.5 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 156.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 28 | 16.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 32.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 12.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 2646.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 2942.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 2748.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 17.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 160.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 156.5 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 175.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 333.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 292.5 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 293.5 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 3584.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 3469.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 3449.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 4330.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 3224.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 7.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 26.5 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 50.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 29.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 42.5 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 39.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 48 | 4.5 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 28 | 19.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 12.5 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 13.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 22.5 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 16.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 259.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 51.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 345.5 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 Nef-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of Nef Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 Nef-specific CD8+ T-cells/million cells |
Secondary
Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells
The cytokine co-expression profile was defined by the frequency of P17-specific CD4+ T-cells expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 31.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 58.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 22.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 34.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 180.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 56.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 26.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 44.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 24.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 32.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 79.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 33.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 58.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 6 | 1.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 76.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 41.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 39.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 50.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 11.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 26.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 54.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 37.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 26.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 20.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 30 | 12.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 46.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 26.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 24.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 22.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 33.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 44.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 51.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 57.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 88.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 4.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 51.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 28 | 100.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 2.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 4.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 42.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 51.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 22.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 7.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 88.5 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 19.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 44.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 77.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 59.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 72.0 P17-specific CD4+ T-cells/million T-cell |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 41.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 25.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 28 | 60.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 30 | 133.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 48 | 72.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 6 | 20.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 28 | 27.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 48 | 9.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 25.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 71.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 75.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 82.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 54.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 74.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 6.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 21.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 20.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 14.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 42.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 16.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 34.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 6.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 22.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 20.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 42.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 42.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 49.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 35.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 43.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 23.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 20.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 11.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 16.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 64.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 33.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 15.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 25.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 18.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 35.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 35.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 28.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 40.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 16.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 8.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 71.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 8.5 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 13.0 P17-specific CD4+ T-cells/million T-cell |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 25.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 55.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 25.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 23.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 30.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 28 | 80.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 10.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 21.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 41.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 25.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 45.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 64.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 56.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 26.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 22.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 41.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 12.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 21.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 73.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 83.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 31.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 20.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 36.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 28.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 16.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 35.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 6 | 6.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 33.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 68.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 65.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 42.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 23.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 37.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 37.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 9.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 26.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 27.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 21.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 32.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 30.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 26.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 48.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 70.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 6.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 39.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 64.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 56.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 34.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 30.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 49.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 22.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 19.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 48 | 150.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 84.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 30 | 198.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 57.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 73.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 88.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 26.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 76.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 22.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 1.00 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 14.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 1.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 24.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 27.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 26.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 25.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 25.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 31.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 6.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 17.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 13.5 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 14.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | IL-2, Week 6 | 1.0 P17-specific CD4+ T-cells/million T-cell |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 12.5 P17-specific CD4+ T-cells/million T-cell |
Secondary
Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells
The cytokine co-expression profile was defined by the frequency of P17-specific CD8+ T-cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ.
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 47.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 48 | 2.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 6 | 17.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 11.5 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 52.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 25.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 28 | 15.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 66.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 69.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 2.5 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 11.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 497.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 67.5 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 28 | 19.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 642.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 694.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 276.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 406.0 P17-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 60.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 111.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 107.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 6 | 16.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 61.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 76.5 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 28 | 37.5 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 29.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 27.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 39.5 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 6.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 9.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 17.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 901.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 1144.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 1070.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 1199.5 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 1049.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 6 | 23.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 28 | 42.5 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 30 | 3.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 28 | 37.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 7.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 7.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 6 | 2.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 28 | 40.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 6 | 17.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 13.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 29.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 5.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 811.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 733.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 880.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 49.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 66.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 63.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 28 | 4.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Week 6 | 17.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 1059.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 1279.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 994.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 1450.5 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 1617.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 11.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 19.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 20.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 29.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 48 | 21.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 30 | 22.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Week 6 | 4.5 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 110.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 128.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 130.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 164.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 130.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 7.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P17-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P17 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P17-specific CD8+ T-cells/million cells |
Secondary
Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells
The cytokine co-expression profile was defined by the frequency of P24-specific CD4+ T-cells expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 45.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 21.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 31.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 62.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 46.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 64.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 79.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 30.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 83.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 113.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 68.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 87.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 122.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 55.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 6 | 86.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 127.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 63.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 49.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 70.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 86.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 68.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 28 | 2.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 85.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 59.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 30 | 22.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 41.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 41.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 19.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 79.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 28 | 125.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 30.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 24.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 115.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 78.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 79.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 34.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 41.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 98.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 65.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 19.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 67.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 30 | 22.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 24.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 124.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 57.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 26.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 28.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 139.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 34.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 22.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 99.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 157.5 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 96.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 52.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 43.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 125.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 65.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 6 | 140.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 28 | 194.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 30 | 110.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 48 | 160.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 3.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 6 | 6.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 11.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 32.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 40.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 112.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 118.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 167.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 171.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 22.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 36.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 31.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 51.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 34.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 30.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 72.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 13.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 48.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 6.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 96.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 81.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 94.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 106.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 102.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 42.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 34.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 41.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 43.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 40.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 20.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 80.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 36.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 44.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 31.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 30.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 21.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 14.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 21.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 85.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 84.5 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 54.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 57.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 61.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 38.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 58.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 41.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 46.0 P24-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 53.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 105.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 64.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 20.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 119.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 58.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 35.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 58.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 98.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 30.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 58.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 33.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 89.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 28 | 165.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 6 | 110.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 21.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 87.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 59.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 4.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 124.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 39.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 40.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 31.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 5.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 49.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 128.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 72.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 41.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 32.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 74.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 34.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 35.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 114.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 29.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 70.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 46.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 62.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 26.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 48.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 24.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 120.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 38.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 129.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 59.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 106.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 2.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 137.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 9.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 99.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 13.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 83.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 17.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 52.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 68. P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 22.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 48 | 125.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 266.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 224.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 271.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 30 | 130.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 61.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 233.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 53.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 56.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 164.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 28 | 15.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 29.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 52.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 12.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 46.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 20.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 36.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 39.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 29.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 27.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 25.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 45.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 21.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 32.5 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 16.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 29.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 48 | 19.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 2.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 30 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 24.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 17.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 16.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 36.0 P24-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 71.0 P24-specific CD4+ T-cells/million cells |
Secondary
Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells
The cytokine co-expression profile was defined by the frequency of P24-specific CD8+ T-cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ.
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 5122.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 7.5 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 30 | 38.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 299.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 246.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 30 | 8.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 471.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 69.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 4570.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 53.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 37.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 236.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 291.5 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 5862.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 11.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 29.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 54.5 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 4897.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 5056.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 6 | 5.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 19.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 37.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 6 | 10.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 6910.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 5096.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 4345.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 28 | 25.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 4358.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 4974.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 30 | 18.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 20.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 2.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 28 | 21.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 48 | 4.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 30 | 35.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 26.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 19.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 18.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 50.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 2.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 586.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 26.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 390.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 492.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 82.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 313.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 423.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 40.5 P24-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 71.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 19.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 28 | 7.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 5268.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 3.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 51.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 4657.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 319.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 6 | 2.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 283.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 28 | 12.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 18.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 471.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 5933.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 47.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 48 | 11.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 54.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 28 | 28.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 30 | 1.5 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 89.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 40.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 48.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 74.5 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 17.5 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 6749.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 9141.5 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 6198.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 7770.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 6070.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 11.5 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 28.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 22.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 22.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 25.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 705.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 751.5 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 484.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 761.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 497.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 8.5 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 P24-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of P24 Antigen-specific CD8+ T-cells | CD40L, Week 6 | 26.5 P24-specific CD8+ T-cells/million cells |
Secondary
Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells
The cytokine co-expression profile was defined by the frequency of reverse transcriptase (RT)-specific CD4+ T-cells expressing CD40L and/or IL-2 and/or tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 183.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 64.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 6 | 34.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 7.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 118.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 24.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 22.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 63.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 25.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 31.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 36.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 71.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 71.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 15.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 156.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 89.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 26.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 35.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 100.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 39.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 175.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 14.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 141.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 30 | 25.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 371.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 18.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 48 | 20.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 21.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 61.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 96.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 131.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 26.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 78.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 29.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 141.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 40.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 185.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 491.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 85.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 142.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 59.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 459.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 476.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 21.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 7.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 23.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 85.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 22.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 9.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 18.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 35.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 7.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 57.5 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 21.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 42.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 44.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 18.0 RT-specific CD4+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 78.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 6 | 40.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 30 | 90.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 6 | 12.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 30 | 5.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 48 | 8.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 18.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 69.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 11.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 25.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 27.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 27.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 40.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 46.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 43.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 179.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 80.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 57.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 45.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 39.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 116.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 22.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 23.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 31.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 17.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 76.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 22.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 7.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 24.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 48 | 44.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 17.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 16.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 25.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 315.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 95.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 91.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 66.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 6.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 96.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 17.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 20.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 11.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 64.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 17.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 20.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 21.5 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 14.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 262.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 70.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 48.0 RT-specific CD4+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 58.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 5.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 44.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 41.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 7.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 21.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 27.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 65.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 85.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 23.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 23.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 346.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 121.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 73.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 123.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 21.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 40.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 20.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 14.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 90.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 30.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 22.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 132.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 15.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 81.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 37.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 337.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 6 | 14.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 22.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 77.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 181.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 6 | 20.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 6 | 13.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 20.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 30 | 28.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 9.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 48 | 3.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 14.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Pre-vaccination | 46.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 48 | 30.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 22.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 6 | 27.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 33.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 48 | 4.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 23.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 30 | 30.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 27.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IL-2, Pre-vaccination | 9.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 30 | 36.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 28 | 28.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 48 | 55.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 48 | 39.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 30 | 47.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Week 6 | 32.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 28 | 44.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 34.5 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Week 28 | 15.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Pre-vaccination | 23.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 56.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 6 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Week 6 | 28.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 48 | 30.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IL-2, Pre-vaccination | 11.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 28 | 19.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 6 | 31.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ, Pre-vaccination | 45.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α, Pre-vaccination | 30.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ, Week 48 | 13.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 19.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 23.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 48 | 30.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L, Week 30 | 135.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_IFN- γ, Week 28 | 23.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 43.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 30 | 41.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 18.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 21.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 49.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α, Week 28 | 41.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD4+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD4+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 76.0 RT-specific CD4+ T-cells/million cells |
Secondary
Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells
The cytokine co-expression profile was defined by the frequency of reverse transcriptase (RT)-specific CD8+ T-cells expressing CD40L and/or IL-2 and/or TNF-α and/or IFN-γ.
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 2959.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 3081.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 30 | 19.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 14.5 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 48 | 2.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 71.5 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 61.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 250.5 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 42.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 232.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 301.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 33.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 271.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 63.5 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 372.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 17.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 3370.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 16.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 3474.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 5410.0 RT-specific CD8+ T-cells/million cells |
| 3D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 60.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 6 | 15.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 28 | 15.5 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 30 | 21.5 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 67.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 70.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 50.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 76.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 63.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 2161.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 2885.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 2355.5 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 2824.5 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 17.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 28.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 7.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 11.5 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 8.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 314.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 360.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 455.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 542.5 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 483.5 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 3187.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 5.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| 2D_HIV Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 454.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 17.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 48.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 3050.5 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 13.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 63.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 28 | 13.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 300.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 3138.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 23.5 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 68.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 3079.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 339.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 30 | 4000.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 28 | 3595.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 6 | 4012.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Pre-vaccination | 18.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 6 | 16.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Pre-vaccination | 3950.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Week 6 | 35.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 28 | 16.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ, Week 48 | 4294.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 30 | 19.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 48 | 109.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IFN- γ_IL-2, Week 48 | 18.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 30 | 97.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 6 | 10.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Pre-vaccination | 410.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 28 | 80.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 28 | 366.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 30 | 490.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Week 6 | 82.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 48 | 404.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L, Pre-vaccination | 12.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α, Pre-vaccination | 84.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 48 | 40.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 30 | 12.5 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ, Week 6 | 471.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 28 | 2.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | TNF-α_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 28 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Week 6 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 30 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | IL-2, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_IFN- γ_IL-2, Week 48 | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α_IFN- γ, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
| Control Group | Cytokine Expression Profile of RT Antigen-specific CD8+ T-cells | CD40L_TNF-α, Pre-vaccination | 1.0 RT-specific CD8+ T-cells/million cells |
Secondary
Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline
Changes from baseline in HIV-1 viral load (ratio of each value over baseline value) were obtained using crude values and expressed in RNA copies/mL. Baseline of HIV-1 viral load was defined as the geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic. Changes from baseline were measured at Week 1 to 28 for the HIV Group, Weeks 30 and 38 for the 3D\_HIV Group and 2D\_HIV Group and from Week 1 to Week 38 for the Control Group.
Time frame: At Weeks 1, 4, 6, 16, 28, 30 and 38
Population: The analysis was performed on the Modified Total vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| 3D_HIV Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 28 | 1.2 RNA copies/mL | Standard Deviation 0.35 |
| 3D_HIV Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 16 | 1.1 RNA copies/mL | Standard Deviation 0.31 |
| 3D_HIV Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 4 | 1.1 RNA copies/mL | Standard Deviation 0.28 |
| 3D_HIV Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 1 | 1.0 RNA copies/mL | Standard Deviation 0.18 |
| 3D_HIV Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 6 | 1.1 RNA copies/mL | Standard Deviation 0.26 |
| 2D_HIV Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 30 | 1.1 RNA copies/mL | Standard Deviation 0.24 |
| 2D_HIV Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 38 | 0.9 RNA copies/mL | Standard Deviation 0.28 |
| Control Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 30 | 1.2 RNA copies/mL | Standard Deviation 0.38 |
| Control Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 38 | 1.2 RNA copies/mL | Standard Deviation 0.32 |
| Control Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 6 | 1.2 RNA copies/mL | Standard Deviation 0.37 |
| Control Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 28 | 1.2 RNA copies/mL | Standard Deviation 0.36 |
| Control Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 4 | 1.1 RNA copies/mL | Standard Deviation 0.32 |
| Control Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 30 | 1.2 RNA copies/mL | Standard Deviation 0.34 |
| Control Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 1 | 0.9 RNA copies/mL | Standard Deviation 0.18 |
| Control Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 38 | 1.2 RNA copies/mL | Standard Deviation 0.43 |
| Control Group | Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline | HIV-1 VL, Week 16 | 1.1 RNA copies/mL | Standard Deviation 0.28 |
Secondary
Geometric Mean Change in HIV-1 VL From Baseline
Changes from baseline in HIV-1 viral load (difference of each value minus baseline value) were obtained using log10-transformed values and expressed in log10-RNA copies/mL. Baseline of HIV-1 viral load was defined as geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic. Changes from baseline were measured at Week 1 to 29 for the HIV Group, Weeks 30 and 38 for the 3D\_HIV Group and 2D\_HIV Group and from Week 1 to Week 38 for the Control Group.
Time frame: At Weeks 1, 4, 6, 16, 28, 30 and 38
Population: The analysis was performed on the Modified Total vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| 3D_HIV Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 28 | 0.1 log10(RNA copies/mL) | Standard Deviation 0.35 |
| 3D_HIV Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 1 | 0.0 log10(RNA copies/mL) | Standard Deviation 0.18 |
| 3D_HIV Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 6 | 0.1 log10(RNA copies/mL) | Standard Deviation 0.26 |
| 3D_HIV Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 4 | 0.0 log10(RNA copies/mL) | Standard Deviation 0.28 |
| 3D_HIV Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 16 | 0.0 log10(RNA copies/mL) | Standard Deviation 0.31 |
| 2D_HIV Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 30 | 0.0 log10(RNA copies/mL) | Standard Deviation 0.24 |
| 2D_HIV Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 38 | 0.0 log10(RNA copies/mL) | Standard Deviation 0.28 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 38 | 0.1 log10(RNA copies/mL) | Standard Deviation 0.32 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 30 | 0.1 log10(RNA copies/mL) | Standard Deviation 0.38 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 38 | 0.1 log10(RNA copies/mL) | Standard Deviation 0.43 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 4 | 0.1 log10(RNA copies/mL) | Standard Deviation 0.32 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 1 | -0.1 log10(RNA copies/mL) | Standard Deviation 0.18 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 30 | 0.1 log10(RNA copies/mL) | Standard Deviation 0.34 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 28 | 0.1 log10(RNA copies/mL) | Standard Deviation 0.36 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 16 | 0.0 log10(RNA copies/mL) | Standard Deviation 0.28 |
| Control Group | Geometric Mean Change in HIV-1 VL From Baseline | HIV-1 VL, Week 6 | 0.1 log10(RNA copies/mL) | Standard Deviation 0.37 |
Secondary
Levels of HIV-1 Viral Load (VL)
HIV-1 VL, using crude values, was expressed in RNA copies/mL and measured from Screening to Week 28 for the HIV Group, Weeks 30, 38 and 48 for the 3D\_HIV Group and 2D\_HIV Group and from Screening to Week 48 for the Control Group.
Time frame: At Screening, Pre-vaccination and at Weeks 1, 4, 6, 16, 28, 30, 38 and 48
Population: The analysis was performed on the Modified Total vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Screening | 13797 RNA Copies/mL |
| 3D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 4 | 14242.5 RNA Copies/mL |
| 3D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Pre-vaccination | 12982 RNA Copies/mL |
| 3D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 1 | 14939 RNA Copies/mL |
| 3D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 6 | 17019 RNA Copies/mL |
| 3D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 16 | 15045 RNA Copies/mL |
| 3D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 28 | 12552.5 RNA Copies/mL |
| 2D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 48 | 11004.5 RNA Copies/mL |
| 2D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 38 | 12248 RNA Copies/mL |
| 2D_HIV Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 30 | 14703 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 38 | 14739 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 48 | 18415 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 30 | 13902 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 1 | 11936 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 28 | 13208 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 38 | 12264.5 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Pre-vaccination | 12688.5 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 30 | 12855.5 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 4 | 11627.5 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 48 | 15266.5 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Screening | 12882.5 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 6 | 15117.5 RNA Copies/mL |
| Control Group | Levels of HIV-1 Viral Load (VL) | HIV-1 VL, Week 16 | 14605 RNA Copies/mL |
Secondary
Levels of HIV-1 VL
HIV-1 VL, using log10 transformed values, was expressed in log10-RNA copies/mL and measured from Screening to Week 28 for the HIV Group, Weeks 30, 38 and 48 for the 3D\_HIV Group and 2D\_HIV Group and from Screening to Week 48 for the Control Group.
Time frame: At Screening, Pre-vaccination and at Weeks 1, 4, 6, 16, 28, 30, 38 and 48
Population: The analysis was performed on the Modified Total vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Screening | 4.14 log10 (RNA Copies/mL) |
| 3D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Pre-vaccination | 4.113 log10 (RNA Copies/mL) |
| 3D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Week 1 | 4.174 log10 (RNA Copies/mL) |
| 3D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Week 6 | 4.231 log10 (RNA Copies/mL) |
| 3D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Week 16 | 4.177 log10 (RNA Copies/mL) |
| 3D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Week 28 | 4.099 log10 (RNA Copies/mL) |
| 3D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Week 4 | 4.153 log10 (RNA Copies/mL) |
| 2D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Week 48 | 4.04 log10 (RNA Copies/mL) |
| 2D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Week 38 | 4.088 log10 (RNA Copies/mL) |
| 2D_HIV Group | Levels of HIV-1 VL | HIV-1 VL, Week 30 | 4.167 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 48 | 4.265 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 38 | 4.168 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 30 | 4.143 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Screening | 4.11 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 28 | 4.12 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Pre-vaccination | 4.103 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 1 | 4.077 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 4 | 4.065 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 6 | 4.179 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 30 | 4.108 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 16 | 4.163 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 38 | 4.089 log10 (RNA Copies/mL) |
| Control Group | Levels of HIV-1 VL | HIV-1 VL, Week 48 | 4.184 log10 (RNA Copies/mL) |
Secondary
Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine.
Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD40L-CD4+ T-cells and F4co-Computed \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD40L-CD4+ T-cells expressing at least interleukin- 2 (IL-2) or another cytokine among interferon-gamma (IFN-γ) and/or tumour necrosis-alpha (TNF-α), as assessed by Intracellular Cytokine Staining (ICS).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 30 | 279.5 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 48 | 210.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 30 | 389.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Pre-vaccination | 297.5 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 28 | 296.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 6 | 287.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 48 | 270.5 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 30 | 1376.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 48 | 1193.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 30 | 369.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Pre-vaccination | 148.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Pre-vaccination | 874.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 6 | 302.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 28 | 210.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 28 | 169.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 28 | 892.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 30 | 245.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 6 | 369.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 48 | 215.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Pre-vaccination | 204.5 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Pre-vaccination | 175.5 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 6 | 229.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 6 | 1189.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 28 | 164.0 CD40L-CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 48 | 341.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Pre-vaccination | 973.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 30 | 298.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Pre-vaccination | 184.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 48 | 177.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 48 | 132.5 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 28 | 261.5 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Pre-vaccination | 287.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 28 | 1115.5 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 30 | 166.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 6 | 258.5 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 6 | 344.5 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 28 | 340.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 28 | 238.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 30 | 273.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 30 | 1198.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 30 | 162.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 6 | 231.5 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 48 | 1006.5 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 6 | 1086.5 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 48 | 174.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Pre-vaccination | 239.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Pre-vaccination | 194.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 28 | 118.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 48 | 369.0 CD40L-CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 6 | 301.5 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 6 | 304.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Pre-vaccination | 945.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 6 | 1090.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 28 | 986.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Pre-vaccination | 195.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 6 | 301.5 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 28 | 241.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Pre-vaccination | 188.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 6 | 230.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 28 | 210.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Pre-vaccination | 294.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 6 | 288.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 28 | 313.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Pre-vaccination | 194.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 28 | 148.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 28 | 487.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 48 | 224.5 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 30 | 229.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 30 | 492.5 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 28 | 203.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Week 6 | 293.5 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 48 | 396.5 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p17, Pre-vaccination | 230.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 48 | 267.5 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Pre-vaccination | 1433.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Pre-vaccination | 235.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 30 | 250.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 28 | 197.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 6 | 1227.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 6 | 144.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Week 6 | 211.5 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | Nef, Pre-vaccination | 263.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 48 | 158.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 28 | 138.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 48 | 1419.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 30 | 1416.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | RT, Week 30 | 162.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Week 6 | 428.5 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | p24, Pre-vaccination | 377.0 CD40L-CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L-CD4+ T-cells Expressing at Least One Cytokine. | F4co-Computed, Week 28 | 1118.0 CD40L-CD4+ T-cells/million T-cells |
Secondary
Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine
Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD40L+CD4+ T-cells and F4co-Computed \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD40L+CD4+ T-cells expressing at least interleukin- 2 (IL-2) or another cytokine among interferon-gamma (IFN-γ) and/or tumour necrosis-alpha (TNF-α), as assessed by Intracellular Cytokine Staining (ICS).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 459.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 227.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 1587.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 30 | 413.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 284.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 30 | 763.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 48 | 451.5 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 517.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 48 | 258.5 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 268.5 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 249.5 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 48 | 486.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 30 | 4039.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 3675.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 596.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 48 | 1947.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 1135.5 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 48 | 261.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 87.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 30 | 1629.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 1588.5 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 30 | 596.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 599.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 378.0 CD40L+CD4+ T-cells/million T-cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 439.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 48 | 299.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 997.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 2506.5 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 1253.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 30 | 1108.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 48 | 1039.5 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 87.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 392.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 179.5 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 30 | 204.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 48 | 146.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 164.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 379.5 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 243.5 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 30 | 242.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 48 | 244.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 339.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 30 | 424.5 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 452.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 381.5 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 48 | 371.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 238.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 1074.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 379.0 CD40L+CD4+ T-cells/million T-cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 30 | 327.5 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 1346.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 486.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 434.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 87.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 379.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 378.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 408.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 2864.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 1433.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 1022.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 228.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 247.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 393.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 281.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 208.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 263.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 379.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 30 | 1157.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 30 | 113.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 204.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 296.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 30 | 401.5 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 786.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 228.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 48 | 404.5 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 267.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 48 | 245.5 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 115.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 1243.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 48 | 87.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 505.5 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 73.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 277.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 108.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 953.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 204.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 30 | 256.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | RT, Week 48 | 222.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | p17, Week 30 | 303.0 CD40L+CD4+ T-cells/million T-cells |
| Control Group | Magnitude of Antigen Specific CD40L+CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 48 | 1251.0 CD40L+CD4+ T-cells/million T-cells |
Secondary
Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine
Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD4+ T-cells and F4co-Computed \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD4+ T-cells expressing at least interleukin- 2 (IL-2) or another cytokine among interferon-gamma (IFN-γ) and/or tumour necrosis-alpha (TNF-α), as assessed by Intracellular Cytokine Staining (ICS).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 794.5 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 983.5 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 2360.5 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 48 | 525.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 30 | 798.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 494.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 1916.5 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 494.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 797.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 494.5 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 463.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 48 | 568.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 2885.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 48 | 797.5 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 48 | 856.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 30 | 988.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 30 | 5376.5 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 30 | 2138.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 784.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 48 | 3266.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 599.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 902.0 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 284.5 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 5024.5 CD4+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 30 | 1220.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 699.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 434.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 1033.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 1998.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 4146.5 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 2374.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 30 | 2538.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 48 | 2544.5 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 390.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 805.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 444.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 30 | 512.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 48 | 356.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 561.5 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 527.5 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 30 | 473.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 48 | 580.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 670.5 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 30 | 708.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 48 | 831.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 442.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 1426.5 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 667.5 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 30 | 540.0 CD4+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 48 | 573.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 977.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 4432.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 759.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 813.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 2459.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 457.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 2068.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 634.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 1680.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 682.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 455.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 726.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 494.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 337.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 455.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 48 | 470.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 474.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 30 | 477.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 48 | 377.5 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 30 | 357.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 578.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 283.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 416.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 433.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 2420.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 323.5 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 30 | 536.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 562.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p17, Week 48 | 498.5 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 386.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 733.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 48 | 2398.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 943.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 30 | 2593.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 883.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 2052.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 384.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 30 | 944.5 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | p24, Week 48 | 891.0 CD4+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD4+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 2711.5 CD4+ T-cells/million cells |
Secondary
Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine
Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD8+ T-cells and F4co-Computed \[frequency of CD8+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD8+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD8+ T-cells expressing at least interleukin- 2 (IL-2) or another cytokine among interferon-gamma (IFN-γ) and/or tumour necrosis-alpha (TNF-α), as assessed by Intracellular Cytokine Staining (ICS).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 6187.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 48 | 818.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 30 | 510.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 3141.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 3699.5 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 707.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 829.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 2641.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 16727.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 48 | 2444.5 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 30 | 2790.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 30 | 3262.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 3724.5 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 48 | 5900.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 17526.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 15895.5 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 30 | 5525.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 6273.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 30 | 15659.5 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 48 | 3299.5 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 4972.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 48 | 16143.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 858.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 5364.0 CD8+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 3187.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 48 | 21063.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 6826.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 3418.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 30 | 3747.5 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 19633.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 19340.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 17186.5 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 30 | 19210.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 2453.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 3497.5 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 3655.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 30 | 3387.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 48 | 2478.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 1212.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 1478.5 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 1419.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 30 | 1467.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 48 | 1669.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 8630.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 5465.5 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 30 | 5064.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 48 | 6371.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 3073.0 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 2860.5 CD8+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 48 | 3462.5 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 1085.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 6181.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 3556.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 17609.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 3054.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 17344.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 5610.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 3663.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 991.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 6248.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 3174.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 3490.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 17839.5 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 3141.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 1055.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 30 | 4538.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 48 | 7410.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 28 | 4332.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 30 | 3970.5 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Pre-vaccination | 4395.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 48 | 4014.5 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Pre-vaccination | 25819.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Pre-vaccination | 2246.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Week 6 | 5174.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 6 | 1681.5 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 6 | 4715.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 28 | 1613.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | Nef, Pre-vaccination | 3796.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 30 | 1524.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 48 | 4565.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p17, Week 48 | 1494.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 48 | 25564.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Pre-vaccination | 8435.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 30 | 29064.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 6 | 10328.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 28 | 25798.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | RT, Week 28 | 4292.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 28 | 8207.0 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | p24, Week 30 | 8923.5 CD8+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific CD8+ T-cells Expressing at Least One Cytokine | F4co-Computed, Week 6 | 29786.5 CD8+ T-cells/million cells |
Secondary
Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2)
Magnitude was defined as the frequency of proteins 17, 24, Nef, reverse transcriptase (RT) - specific CD40L+CD4+ T-cells and F4co-Computed \[frequency of CD4+ T-cells expressing markers in the response to the F4co fusion protein was estimated by adding individual frequencies of CD4+ T-cells to each of the 4 antigens (Nef, p17, p24, RT)\] CD40L+CD4+ T-cells expressing at least interleukin- 2 (IL-2), as assessed by Intracellular Cytokine Staining (ICS).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 6 | 271.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Pre-vaccination | 140.5 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 30 | 672.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 28 | 818.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 48 | 100.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 30 | 1155.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 30 | 173.5 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Pre-vaccination | 111.5 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 6 | 226.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Pre-vaccination | 430.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 28 | 132.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 48 | 166.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 30 | 2495.5 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 6 | 2559.5 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 28 | 157.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 48 | 937.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 48 | 365.5 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Pre-vaccination | 158.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Pre-vaccination | 43.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 28 | 297.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 48 | 197.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 30 | 256.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 6 | 521.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 6 | 1160.0 CD40L+CD+ T-cells/million cells |
| 3D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 28 | 184.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 6 | 226.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Pre-vaccination | 469.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 6 | 1686.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 28 | 677.5 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 30 | 681.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 48 | 534.5 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Pre-vaccination | 42.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 6 | 219.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 30 | 104.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 48 | 96.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Pre-vaccination | 92.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 28 | 109.5 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 30 | 115.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 48 | 120.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Pre-vaccination | 121.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 6 | 222.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 30 | 183.5 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 48 | 129.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Pre-vaccination | 126.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 28 | 97.5 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 28 | 159.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 6 | 837.0 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 28 | 279.5 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 30 | 245.5 CD40L+CD+ T-cells/million cells |
| 2D_HIV Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 48 | 170.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 28 | 751.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Pre-vaccination | 132.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 6 | 226.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 6 | 259.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 28 | 118.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 6 | 1070.5 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Pre-vaccination | 43.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 28 | 178.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 28 | 297.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 6 | 253.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 28 | 122.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 6 | 2014.5 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Pre-vaccination | 97.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Pre-vaccination | 435.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Pre-vaccination | 127.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 6 | 130.5 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 48 | 120.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 28 | 68.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 48 | 26.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 30 | 106.5 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 30 | 42.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 6 | 557.5 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Week 48 | 78.5 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 28 | 29.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 30 | 180.5 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Pre-vaccination | 364.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Week 6 | 45.5 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 6 | 127.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 28 | 120.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | Nef, Pre-vaccination | 46.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 30 | 155.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Week 48 | 119.5 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 48 | 365.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 28 | 101.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Pre-vaccination | 116.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | RT, Week 6 | 174.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 30 | 521.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p24, Pre-vaccination | 129.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | F4co-Computed, Week 28 | 345.0 CD40L+CD+ T-cells/million cells |
| Control Group | Magnitude of Antigen Specific Cluster of Differentiation-40 Ligand (CD40L)+CD4+ T-cells Expressing at Least Interleukin-2 (IL-2) | p17, Pre-vaccination | 105.0 CD40L+CD+ T-cells/million cells |
Secondary
Mean Change in CD4 Cell Count From Baseline
Baseline for CD4 cell count analysis was defined as the mean of values measured in blood taken at Screening and at pre vaccination (PRE). Result determination, using crude values, was done from week 1 to 28 for the HIV Group, weeks 30, 38 and 48 for the 3D\_HIV Group and 2D\_HIV Group and from week 1 to week 48 for the Control Group.
Time frame: At Weeks 1, 4, 6, 16, 28, 30, 38 and 48
Population: The analysis was performed on the Modified Total vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 3D_HIV Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 16 | -0.52 CD4 cells/cubic millimeter | Standard Deviation 20.82 |
| 3D_HIV Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 28 | -5.782 CD4 cells/cubic millimeter | Standard Deviation 19.13 |
| 3D_HIV Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 6 | 2.066 CD4 cells/cubic millimeter | Standard Deviation 19.97 |
| 3D_HIV Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 1 | 4.633 CD4 cells/cubic millimeter | Standard Deviation 16.53 |
| 3D_HIV Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 4 | -0.201 CD4 cells/cubic millimeter | Standard Deviation 17.97 |
| 2D_HIV Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 30 | -5.641 CD4 cells/cubic millimeter | Standard Deviation 19.17 |
| 2D_HIV Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 38 | -4.224 CD4 cells/cubic millimeter | Standard Deviation 22.97 |
| 2D_HIV Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 48 | -9.859 CD4 cells/cubic millimeter | Standard Deviation 18.66 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 48 | -3.915 CD4 cells/cubic millimeter | Standard Deviation 19.56 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 38 | -4.626 CD4 cells/cubic millimeter | Standard Deviation 20.01 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 30 | -2.417 CD4 cells/cubic millimeter | Standard Deviation 20.31 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 48 | -13.82 CD4 cells/cubic millimeter | Standard Deviation 18.67 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 6 | -1.713 CD4 cells/cubic millimeter | Standard Deviation 19.68 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 16 | -2.568 CD4 cells/cubic millimeter | Standard Deviation 19.68 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 1 | 0.589 CD4 cells/cubic millimeter | Standard Deviation 17.98 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 4 | -1.212 CD4 cells/cubic millimeter | Standard Deviation 18.58 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 28 | -4.421 CD4 cells/cubic millimeter | Standard Deviation 16.06 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 30 | -4.403 CD4 cells/cubic millimeter | Standard Deviation 19.88 |
| Control Group | Mean Change in CD4 Cell Count From Baseline | CD4, Week 38 | -5.936 CD4 cells/cubic millimeter | Standard Deviation 16.85 |
Secondary
Number of Seropositive Subjects for Anti-F4co Antibodies
Seropositivity rates for antibodies against F4co antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 42 milli-ELISA units per milliliter (mEL.U/mL).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 48 | 39 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Pre-vaccination | 44 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 28 | 44 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 30 | 43 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 6 | 44 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 28 | 45 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Pre-vaccination | 45 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 6 | 43 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 30 | 42 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 48 | 43 Participants |
| Control Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 28 | 89 Participants |
| Control Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Pre-vaccination | 89 Participants |
| Control Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 6 | 87 Participants |
| Control Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 48 | 37 Participants |
| Control Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 30 | 38 Participants |
| Control Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 6 | 40 Participants |
| Control Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Week 28 | 39 Participants |
| Control Group | Number of Seropositive Subjects for Anti-F4co Antibodies | Anti-F4co, Pre-vaccination | 40 Participants |
Secondary
Number of Seropositive Subjects for Anti-Nef Antibodies
Seropositivity rates for antibodies against Nef antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 494 milli-ELISA units per milliliter (mEL.U/mL).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 48 | 33 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Pre-vaccination | 22 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 28 | 24 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 30 | 42 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 6 | 38 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 28 | 31 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Pre-vaccination | 28 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 6 | 35 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 30 | 28 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 48 | 27 Participants |
| Control Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 28 | 55 Participants |
| Control Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Pre-vaccination | 50 Participants |
| Control Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 6 | 73 Participants |
| Control Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 48 | 18 Participants |
| Control Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 30 | 20 Participants |
| Control Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 6 | 17 Participants |
| Control Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Week 28 | 20 Participants |
| Control Group | Number of Seropositive Subjects for Anti-Nef Antibodies | Anti-Nef, Pre-vaccination | 21 Participants |
Secondary
Number of Seropositive Subjects for Anti-P17 Antibodies
Seropositivity rates for antibodies against P17 antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 187 milli-ELISA units per milliliter (mEL.U/mL).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 28 | 37 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 6 | 39 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Pre-vaccination | 35 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 48 | 31 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 30 | 41 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 48 | 33 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Pre-vaccination | 38 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 6 | 37 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 28 | 38 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 30 | 35 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 28 | 75 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 6 | 76 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Pre-vaccination | 73 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 48 | 31 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Pre-vaccination | 34 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 6 | 33 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 30 | 31 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P17 Antibodies | Anti-P17, Week 28 | 32 Participants |
Secondary
Number of Seropositive Subjects for Anti-P24 Antibodies
Seropositivity rates for antibodies against P24 antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 119 milli-ELISA units per milliliter (mEL.U/mL).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 48 | 39 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Pre-vaccination | 42 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 28 | 43 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 30 | 43 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 6 | 43 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 28 | 44 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Pre-vaccination | 45 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 6 | 43 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 30 | 41 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 48 | 42 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 28 | 87 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Pre-vaccination | 87 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 6 | 86 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 48 | 35 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 30 | 36 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 6 | 38 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Week 28 | 37 Participants |
| Control Group | Number of Seropositive Subjects for Anti-P24 Antibodies | Anti-P24, Pre-vaccination | 38 Participants |
Secondary
Number of Seropositive Subjects for Anti-RT Antibodies
Seropositivity rates for antibodies against RT antigen were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA), with a reference cut-off value greater than or equal to (≥) 125 milli-ELISA units per milliliter (mEL.U/mL).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 48 | 38 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Pre-vaccination | 40 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 28 | 44 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 30 | 42 Participants |
| 3D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 6 | 43 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 28 | 45 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Pre-vaccination | 42 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 6 | 42 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 30 | 41 Participants |
| 2D_HIV Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 48 | 41 Participants |
| Control Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 28 | 89 Participants |
| Control Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Pre-vaccination | 82 Participants |
| Control Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 6 | 85 Participants |
| Control Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 48 | 37 Participants |
| Control Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 30 | 38 Participants |
| Control Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 6 | 40 Participants |
| Control Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Week 28 | 38 Participants |
| Control Group | Number of Seropositive Subjects for Anti-RT Antibodies | Anti-RT, Pre-vaccination | 39 Participants |
Secondary
Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens
Breadth was assessed only for the CD4+ T-cells and was measured by evaluating response to at least 1, 2, 3 or all 4 antigens: proteins 17, 24, Nef, reverse transcriptase (RT).
Time frame: During the entire study period - up to Week 48 (Pre-vaccination, Weeks 6, 28, 30 and 48 for the 3D_HIV Group, 2D_HIV Group and Control Group and at Pre-vaccination, Weeks 6 and 28 for the HIV Group)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom CMI assay or humoral results were available against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 30 | 30 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 28 | 4 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 6 | 24 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 28 | 2 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Pre-vaccination | 19 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 30 | 15 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 6 | 12 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Pre-vaccination | 4 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Pre-vaccination | 11 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 48 | 23 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 6 | 6 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 48 | 17 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Pre-vaccination | 30 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 48 | 5 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 28 | 19 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 6 | 28 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 30 | 8 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 30 | 24 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 28 | 13 Participants |
| 3D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 48 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 28 | 11 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 28 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 30 | 11 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 28 | 3 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Pre-vaccination | 8 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 30 | 20 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Pre-vaccination | 25 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 48 | 4 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Pre-vaccination | 3 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 6 | 32 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 48 | 1 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 48 | 7 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 6 | 24 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 48 | 19 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 6 | 12 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Pre-vaccination | 16 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 6 | 6 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 30 | 2 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 28 | 22 Participants |
| 2D_HIV Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 30 | 6 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 28 | 41 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Pre-vaccination | 55 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Pre-vaccination | 35 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Pre-vaccination | 19 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Pre-vaccination | 7 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 6 | 60 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 6 | 48 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 6 | 24 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 6 | 12 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 28 | 24 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 28 | 8 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 28 | 5 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 30 | 14 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 28 | 1 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 28 | 2 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 30 | 5 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 28 | 4 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 28 | 7 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 30 | 3 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 48 | 13 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 6 | 0 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 30 | 0 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 6 | 1 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 6 | 2 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Week 6 | 9 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Week 48 | 3 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Pre-vaccination | 3 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Pre-vaccination | 8 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 3 antigens, Week 48 | 2 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 2 antigens, Pre-vaccination | 18 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 1 antigen, Pre-vaccination | 25 Participants |
| Control Group | Number of Subjects With Response to at Least 1, 2, 3 or 4 Antigens | 4 antigens, Week 48 | 0 Participants |
Secondary
Percentage of Subjects With ART (Anti-Retroviral Therapy) Initiation and HIV-related Clinical Events
Only actual ART initiations were reported under the category ART initiation. HIV-related clinical events were defined as: clinical disease progression, or confirmed VL \> 100.000 copies/mL, or confirmed CD4 cell count \< 350 cells/ cubic millimeter (mm3).
Time frame: During the entire study period (up to Week 48)
Population: The analysis was performed on the Modified Total vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3D_HIV Group | Percentage of Subjects With ART (Anti-Retroviral Therapy) Initiation and HIV-related Clinical Events | HIV related clinical events | 9.8 Percentage of participants |
| 3D_HIV Group | Percentage of Subjects With ART (Anti-Retroviral Therapy) Initiation and HIV-related Clinical Events | ART initiation | 8.2 Percentage of participants |
| 2D_HIV Group | Percentage of Subjects With ART (Anti-Retroviral Therapy) Initiation and HIV-related Clinical Events | HIV related clinical events | 10.9 Percentage of participants |
| 2D_HIV Group | Percentage of Subjects With ART (Anti-Retroviral Therapy) Initiation and HIV-related Clinical Events | ART initiation | 6.3 Percentage of participants |
| Control Group | Percentage of Subjects With ART (Anti-Retroviral Therapy) Initiation and HIV-related Clinical Events | HIV related clinical events | 10.0 Percentage of participants |
| Control Group | Percentage of Subjects With ART (Anti-Retroviral Therapy) Initiation and HIV-related Clinical Events | ART initiation | 8.3 Percentage of participants |
Secondary
Percentage of Subjects With Plasmatic HIV-1 Viral Load Decrease Higher Than (>) 1
The proportion of subjects with \>1 decrease of HIV-1 VL, was determined using log10-transformed values.
Time frame: At Week 48
Population: The analysis was performed on the Modified Total vaccinated cohort, which included all subjects with at least one vaccine administration documented who complied with the protocol-defined criteria and with sufficient data to perform the efficacy analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 3D_HIV Group | Percentage of Subjects With Plasmatic HIV-1 Viral Load Decrease Higher Than (>) 1 | 0.00 Percentage of participants |
| 2D_HIV Group | Percentage of Subjects With Plasmatic HIV-1 Viral Load Decrease Higher Than (>) 1 | 0.00 Percentage of participants |
| Control Group | Percentage of Subjects With Plasmatic HIV-1 Viral Load Decrease Higher Than (>) 1 | 0.00 Percentage of participants |